SS
ARQT icon

SBI Securities’s Arcutis Biotherapeutics ARQT Stock Holding History

SBI Securities’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.4K Buy
549
+207
+61% +$4.82K ﹤0.01% 1673
2026
Q1 		$8.06K Sell
342
-747
-69% -$19.1K ﹤0.01% 1825
2025
Q4 		$31.6K Buy
1,089
+833
+325% +$21.3K ﹤0.01% 1267
2025
Q3 		$4.83K Sell
256
-43
-14% -$678 ﹤0.01% 2063
2025
Q2 		$4.19K Sell
299
-1,038
-78% -$14.6K ﹤0.01% 2066
2025
Q1 		$20.9K Buy
1,337
+1,095
+452% +$15.4K ﹤0.01% 1313
2024
Q4 		$3.37K Buy
+242
New +$2.65K ﹤0.01% 2077

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

SBI Securities's ARQT Position: Q2 2026 in Review

SBI Securities increased its Arcutis Biotherapeutics (ARQT) stake by 61% in Q2 2026, buying an estimated $4.82K and bringing the position to 549 shares worth $14.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1673.

SBI Securities first reported a position in ARQT in Q4 2024 and has held it in 7 quarters since. The position peaked at $31.6K in Q4 2025. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • SBI Securities held 549 shares of Arcutis Biotherapeutics worth $14.4K as of Q2 2026.
  • SBI Securities bought 207 Arcutis Biotherapeutics shares in Q2 2026, an estimated $4.82K.
  • Arcutis Biotherapeutics made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #1673 holding.
  • SBI Securities first reported a position in Arcutis Biotherapeutics in Q4 2024 and has held it in 7 quarters since.
  • SBI Securities's Arcutis Biotherapeutics position peaked at $31.6K in Q4 2025.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.